financetom
Business
financetom
/
Business
/
Kroger names PepsiCo executive David Kennerley as CFO
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Kroger names PepsiCo executive David Kennerley as CFO
Feb 12, 2025 5:43 AM

Feb 12 (Reuters) -

Kroger ( KR ) said on Wednesday PepsiCo executive David

Kennerley would succeed Todd Foley as the company's chief

financial officer, effective April 3.

Foley had taken over the role on an interim basis when

former CFO Gary Millerchip stepped down last February.

Kroger ( KR ) in December

ended

a two-year effort to merge with rival Albertsons ( ACI ),

after courts blocked the deal arguing it would lead to higher

prices for shoppers and reduced bargaining leverage for

unionized workers.

Albertsons ( ACI ) had also sued Kroger ( KR ) alleging a breach of

contract that caused the deal's demise.

Foley will retire as interim CFO at the end of Kroger's ( KR )

fiscal year 2024 reporting cycle and serve on the senior

leadership team to support the transition until the end of its

first quarter.

"He (Kennerley) brings to Kroger ( KR ) deep experience leading

a broad-cross section of U.S. and international finance teams

which helped PepsiCo ( PEP ) create shareholder value for nearly 25

years," said Kroger ( KR ) CEO Rodney McMullen.

Kennerley has been senior vice president and CFO for

PepsiCo Europe since March 2020.

In the third quarter, Kroger ( KR ) beat same-store sales

estimates thanks to a

surge in demand

for its lower-priced and freshly sourced groceries, as it

competed with retailers such as Walmart ( WMT ) and Amazon.com ( AMZN )

.

The company, whose shares surged 34% in 2024, has also

been spending on improving its online shopping experience.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
AbbVie, Xilio Collaborate on Tumor-Activated Immunotherapies
AbbVie, Xilio Collaborate on Tumor-Activated Immunotherapies
Feb 12, 2025
08:18 AM EST, 02/12/2025 (MT Newswires) -- AbbVie ( ABBV ) and Xilio Therapeutics (XLO) said Wednesday they are collaborating and have signed an option-to-license agreement to develop tumor-activated, antibody-based immunotherapies, including masked T-cell engagers. The companies said they will combine Xilio's tumor-activation technology with AbbVie's ( ABBV ) research and development efforts in oncology. As part of the deal,...
Lazard Posts Increase in Assets Under Management for January
Lazard Posts Increase in Assets Under Management for January
Feb 12, 2025
08:19 AM EST, 02/12/2025 (MT Newswires) -- Lazard ( LAZ ) reported preliminary assets under management Wednesday of $233.02 billion as of Jan. 31, up from $226.33 billion a month earlier. The asset management firm reported a market appreciation of $6.1 billion, foreign exchange appreciation of $400 million, and net inflows of $300 million for January. ...
Kroger names PepsiCo executive David Kennerley as CFO
Kroger names PepsiCo executive David Kennerley as CFO
Feb 12, 2025
Feb 12 (Reuters) - Kroger ( KR ) said on Wednesday PepsiCo executive David Kennerley would succeed Todd Foley as the company's chief financial officer, effective April 3. Foley had taken over the role on an interim basis when former CFO Gary Millerchip stepped down last February. Kroger ( KR ) in December ended a two-year effort to merge with...
AnaptysBio's Rheumatorid Arthritis Drug Meets Primary Endpoint in Phase 2 Trial; Shares Rise
AnaptysBio's Rheumatorid Arthritis Drug Meets Primary Endpoint in Phase 2 Trial; Shares Rise
Feb 12, 2025
08:20 AM EST, 02/12/2025 (MT Newswires) -- AnaptysBio ( ANAB ) said Wednesday that a phase 2b trial of its investigational drug rosnilimab to treat moderate-to-severe rheumatoid arthritis achieved its primary and secondary endpoints. Patients in the study received either 100 milligram or 400 milligram doses of rosnilimab every four weeks, 600 milligrams every two weeks, or placebo, the company...
Copyright 2023-2025 - www.financetom.com All Rights Reserved